M42, a global health champion powered by AI and technology, has signed a Memorandum of Cooperation (MoC) with Yamagata ...

Tharimmune, Inc., (NASDAQ:THAR) (”Tharimmune” or the “Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, today announced ...

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem ® is a trademark of Actinogen Medical.